Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia

Haematologica

Volumn 99, Issue 8, 2014, Pages

  Valerio, Daria G ^a   Katsman Kuipers, Jenny E ^a   Jansen, Joop H ^b   Verboon, Lonneke J ^a   de Haas, Valerie ^c   Stary, Jan ^d   Baruchel, André ^e   Zimmermann, Martin ^f   Pieters, Rob ^a   Reinhardt, Dirk ^f   van den Heuvel Eibrink, Marry M ^a   Michel Zwaan, C ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Dutch Childhood Oncology Group DCOG   (Netherlands)

^d CHARLES UNIVERSITY   (Czech Republic)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

DNMT3A; IDH; Pediatric acute myeloid leukemia; TET2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADDITIONAL SEX COMBS LIKE 1 PROTEIN; AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEAR RECEPTOR BINDING SET DOMAIN PROTEIN 1; NUCLEOPHOSMIN; NUCLEOPORIN 98; PROTEIN; PROTEIN TYROSINE KINASE; TET2 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DNA METHYLATION; EPIGENETICS; FEMALE; GENE MUTATION; GENE TRANSLOCATION; HISTONE MODIFICATION; HUMAN; LETTER; MALE; ONCOGENE K RAS; PHENOTYPE; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; CHROMOSOME ANALYSIS; CHROMOSOME MAP; COHORT ANALYSIS; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROCEDURES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME MAPPING; COHORT STUDIES; CYTOGENETIC ANALYSIS; EPIGENESIS, GENETIC; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION;

EID: 84905157456     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.094565     Document Type: Letter

References (15)

1. Downing JR, Shannon KM. Acute leukemia: A pediatric perspective. Cancer Cell. 2002; 12(2): 437-45.
2. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12(9): 599-612.
3. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28(14): 2348-55.
4. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29(10): 1373-81.
5. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010; 24(10): 1799-804.
6. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011; 118(26): 6920-9.
7. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012; 26(5): 1106-7.
8. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6): 553-67.
9. Ernst T, Pflug A, Rinke J, Ernst J, Bierbach U, Beck JF, et al. A somatic EZH2 mutation in childhood acute myeloid leukemia. Leukemia. 2012; 26(7): 1701-3.
10. Liang DC, Liu HC, Yang CP, Jaing TH, Hung IJ, Yeh TC, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2 and DNMT3A. Blood. 2013; 121(15): 2988-95.
11. Hollink IHIM, Feng Q, Danen-van Oorschot A, Arentsen-Peters STCJM, Verboon LJ, Zhang P, et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia. 2012; 26(2): 371-3.
12. Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia. 2011; 25(11): 1704-10.
13. Langemeijer SMC, Jansen JH, Hooijer J, van Hoogen P, StevensLinders E, Massop M, et al. TET2 mutations in childhood leukemia. Leukemia. 2011; 25(1): 189-92.
14. Balgobind BV, Hollink IHIM, Arentsen-Peters STCJM, Zimmermann M, Harbott J, Beverloo HB, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011; 96(10): 1478-87.
15. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2): 264-78.